Speaker：Dr. Stuart Lipton (Samford University)

Title：Use of isogenic human iPSCs to elucidate redox-mediated pathways to Parkinson’s, Alzheimer’s, and other neurodegenerative disorders 

Time and Venue:    01-July-2014; 17:00;

KIZ main building, 3nd floor conference room 327

Selected Publications: of Dr. Stuart Lipton

　　Choi Y-B, Tenneti L, Le DA, Ortiz J, Bai G, Chen H-SV, Lipton SA. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nature Neurosci 2000; 3:15-21. 

　　Digicaylioglu M, Lipton SA. Erythropoietin mediates neuroprotection via cross-talk between the Jak2 and NF-kB signalling cascades. Nature 2001; 412: 641-647. 

　　Chatterton JE, Awobuluyi M, Premkumar LS, Takahashi H, Talantova M, Shin Y, Cui J, Tu S, Sevarino KA, Nakanishi N, Tong G, Lipton SA, Zhang D. Excitatory glycine receptor containing the NR3 family of NMDA receptor subunits. Nature 2002; 415: 793-798. 

　　Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC, Lipton SA. S-Nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002; 297:1186-1190. 

　　Lipton SA. Concepts: Turning down but not off—Neuroprotection requires a paradigm shift in drug development.Nature 2004; 428: 473. 

　　Uehara T, Nakamura T, Yao D, Shi Z-Q, Gu Z, Masliah E, Nomura Y, Lipton SA. Nitrosylation of protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 2006; 441: 513-517. 

　　Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nature Rev Drug Disc 2006; 5:160-170. 

　　Takahashi H, Shin Y, Cho SJ, Zago WM, Nakamura T, Gu Z, Ma Y, Furukawa H, Liddington R, Zhang D, Tong G, Chen HS, Lipton SA. Hypoxia enhances NMDAR S-nitrosylation via thiol oxygen sensor. Neuron 2007; 53: 53-64. 

　　Lipton SA. Pathologically activated therapeutics for neuroprotection. Nature Rev Neurosci 2007; 8: 803-808. 

　　Cho D-H, Nakamura T, Fang J, Cieplak P, Godzik A, Gu Z, Lipton SA. S-Nitrosylation of Drp1 mediates beta-amyloid–related mitochondrial fission and neuronal injury. Science 2009; 324: 102-105. PMCID: PMC Journal – In Process. 

　　Okamoto S-i , Pouladi M, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Chen H-SV, Tong G, Hayden MR, Lipton SA. Balance between synaptic versus extrasynaptic NMDA receptor activity influences neurotoxicity. Nature Med 2009; 15:1407-1413. PMCID: PMC2789858. 

　　Larsen RS, Corlew R, Henson MA, Roberts AC, Mishina M, Watanabe M, Lipton SA, NakanishiN, Pérez-Otaño I, Weinberg RJ, Philpot BD. NR3A-containing NMDA receptors promote neurotransmitter release and spike timing-dependent plasticity. Nature Neurosci 2011; 14:338-344. 

　　Ambasudhan R, Talantova M, Coleman R, Yuan X, Zhu S, Lipton SA, Ding S. Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. Cell Stem Cell 2011; 9:113-118. 

　　Marco S, Giralt A, Petrovic MM, Pouladi MA, Martínez-Turrillas R, Martínez-Hernández J, Kaltenbach L, Torres-Peraza J, Graham RK, Watanabe M, Luján R, Nakanishi N, Lipton SA, Lo DC, Hayden MR, Alberch J, Wesseling JF, Pérez-Otaño I. Suppressing aberrant GluN3A expression rescues NMDA receptor dysfunction, synapse loss and motor and cognitive decline in Huntington disease models. Nature Med 2013; 19:1030-1038. 

Key laboratory of Animal Models and Human Disease Mechanisms, CAS

30.06.2014